Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate First-In-Human Trial of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Advanced Solid Tumors

PALO ALTO, Calif.--(BUSINESS WIRE)-- #cancer--Immune-Onc Therapeutics Announces IND Clearance to Initiate First-In-Human Trial of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4)

Click to view original post